Avalon Pharmaceuticals, Inc.
Avalon Pharmaceuticals doesn't mind if genes express themselves -- but they should know that anything they express can and will be used against them if they lead to cancer. The biopharmaceutical firm develops cancer therapeutics based on its AvalonRx platform, which identifies compounds that would be best suited to advance in clinical drug development. Lead product AVN944, an inhibitor of hematologic (leukemia, lymphoma, and myeloma) and solid tumor cancers, is an oral drug now in clinical trials. Avalon also has preclinical programs to develop inhibitors through partnerships with other drug companies. The company was acquired by Clinical Data in 2009.
Contact Details
Office Address
Avalon Pharmaceuticals, Inc.
20358 Seneca Meadows Pkwy.
Germantown, MD, USA 20876
Phone: (301) 556-9900
Fax: (301) 556-9910
Executives
President, CEO, and Director
Andrew J. (Drew) Fromkin
SVP, CFO, and Director
C. Evan Ballantyne